Table 1.

Comparison of baseline characteristics

	FOLFOX4 (EACH)		Sorafenib (ORIENTAL)
	n	%	n	%
N	184		150
Age	49.53 (mean)		51 (median)
Male	166	90.2	127	81.7
HBV infection	171	92.9	106	70.7
HCV infection	9	4.9	16	10.7
Child–Pugh stage
A	163	88.6	146	97.3
B	21	11.4	4	2.7
BCLC stage
B	39	21.2
C	145	78.8	143	95.3
Extrahepatic spread	104	56.5	103	68.7